Cabozantinib for advanced renal cell carcinoma: the METEOR and CABOSUN trials
Description: Sumanta Pal, MD of City of Hope, Duarte, CA, discusses the introduction of new data of the new single-agent cabozantinib for advanced renal cell carcinoma. The agent is a dual MET and VEGFR2 inhibitor, and has been assessed in metastatic renal cell carcinoma and other diseases. Dr Pal highlights his involvement in the Phase I trials of cabozantinib’s development in renal cell carcinoma, where impressive responses were observed. He proceeds to highlight that most recently, cabozantinib was used in a Phase III METEOR trial comparing it to the agent everolimus (NCT01865747). This study identified an improvement in response rate, overall survival (OS) and progression-free survival (PFS) for patients with advanced renal cell carcinoma. According to Dr Pal, these findings make the agent the optimal second-line choice in patients with metastatic renal cell carcinoma. He further adds that data from the CABOSUN study (NCT01835158), a clinical trial that compared sunitinib and cabozantinib in the front-line setting, will hopefully be available shortly. Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.
Shared By : VJOncology
Posted on : 08/18/16
Added : 2 years ago